Casi pharmaceuticals announces dosing of first patient of cid-103 in phase 1 clinical trial for relapsed or refractory multiple myeloma

Rockville, md. and beijing, june 10, 2021 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi), a u.s. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced first-patient-in in the phase 1 dose escalation and expansion study of cid-103, an investigational novel anti-cd38 monoclonal antibody, in patients with previously treated, relapsed or refractory multiple myeloma.
CASI Ratings Summary
CASI Quant Ranking